All the news Showing 10 of 248 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Glecaprevir/pibrentasvir effective for people with hepatitis C and severe kidney disease Liz Highleyman / 22 December 2016 A two-drug pangenotypic regimen combining AbbVie's glecaprevir and pibrentasvir demonstrated a high sustained response rate for people with chronic hepatitis C who have severe kidney impairment, according to results from the EXPEDITION-4 study ... Six weeks of sofosbuvir/ledipasvir cures genotype 1 acute hepatitis C in people without HIV Liz Highleyman / 30 November 2016 A short course of sofosbuvir/ledipasvir (Harvoni) taken for 6 weeks cured 100% of HIV-negative people with genotype 1 acute hepatitis C virus (HCV) infection, including those with high viral loads, according to study results ... Grazoprevir triple regimen demonstrates high cure rates, even for hard-to-treat people Liz Highleyman / 23 November 2016 A new three-drug co-formulation containing Merck's grazoprevir plus the investigational agents MK-3682 and ruzasvir was highly effective for people with hepatitis C virus (HCV) genotypes 1, 2 or 3, with sustained response rates ... 8-week triple DAA combo cures most people with genotype 1-6 hepatitis C Liz Highleyman / 21 November 2016 A three-drug regimen of sofosbuvir, velpatasvir and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated people with all hepatitis C virus (HCV) genotypes, while ... Grazoprevir/elbasvir + sofosbuvir highly effective for hard-to-treat genotype 3 hepatitis C patients Liz Highleyman / 14 November 2016 A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV) genotype 3 and liver cirrhosis, matching ... New triple DAA combo cures 96-99% of people with all genotypes of hepatitis C Liz Highleyman / 08 November 2016 A new three-drug regimen of sofosbuvir, velpatasvir and voxilaprevir, taken without ribavirin for 8 weeks, produced sustained virological response in 96% of previously untreated people with all hepatitis C virus (HCV) genotypes, while ... Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir Gilead press release / 27 October 2016 Sofosbuvir/velpatasvir in chronic hepatitis C: hint of added benefit in two of ten subindications IQWIG / 17 October 2016 Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV Achillion press release / 26 September 2016 NICE says yes to another hepatitis C drug NICE / 26 September 2016 ← Prev12345...25Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive